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This  article  presents  the World  Health  Organization’s  (WHO)  recommendations  for the  use  of  vaccines
against  diseases  caused  by  human  papillomaviruses  (HPV)  from  the  WHO  position  paper  on  Human
papillomavirus  vaccines:  WHO  position  paper  – October  2014,  recently  published  in  the  Weekly  Epi-
demiological  Record  [1].  This position  paper  summarizes  the most  recent  developments  in  the  ﬁeld  of
HPV  vaccines  and  the  WHO  position  on  HPV  vaccine  schedules  in  females.  This  document  replaces  the
ﬁrst  WHO  position  paper  on vaccines  against  diseases  caused  by  HPV  published  in  2009  [2].
Footnotes  to this  paper  provide  a  number  of  core  references.  In accordance  with  its mandate  to  provide
guidance  to  Member  States  on  health  policy  matters,  WHO  issues  a series  of  regularly  updated  position
papers  on  vaccines  and  combinations  of vaccines  against  diseases  that  have  an international  public  health
impact.  These  papers  are  concerned  primarily  with  the  use of  vaccines  in  large-scale  immunization  pro-
grammes;  they  summarize  essential  background  information  on  diseases  and  vaccines,  and  conclude  with
WHO’s  current  position  on  the  use  of  vaccines  in the global  context.  This  paper  reﬂects  the  recommen-
dations  of  WHO’s  Strategic  Advisory  Group  of  Experts  (SAGE)  on  immunization.  These  recommendations
were  discussed  by  SAGE  at its  April  2014  meeting.  Evidence  presented  at the  meeting  can be accessed  at
http://www.who.int/immunization/sage/previous/en/index.html.
©  2015  The  Author.  Published  by Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY  license. WHO  position
WHO  recognizes the importance of cervical cancer and other
PV-related diseases as global public health problems and reit-
rates its recommendation that HPV vaccines should be included
n national immunization programmes, provided that: prevention
f cervical cancer and/or other HPV-related diseases constitutes
 public health priority; vaccine introduction is programmatically
easible; sustainable ﬁnancing can be secured; and the cost-
ffectiveness of vaccination strategies in the country or region is
onsidered. Both the quadrivalent and bivalent HPV vaccines have
xcellent safety and efﬁcacy proﬁles.
Strategy for implementation: HPV vaccines should be introduced
s part of a coordinated and comprehensive strategy to prevent
ervical cancer and other diseases caused by HPV. This strategy
hould include education about reducing behaviours that increase
he risk of acquiring HPV infection, training of health workers and
nformation to women about screening, diagnosis and treatment of
recancerous lesions and cancer. The strategy should also include
ncreased access to quality screening and treatment services and
 Address of WHO: Immunization, Vaccines and Biologicals, 20 Ave Appia,
H-1211, Geneva, Switzerland.
ttp://dx.doi.org/10.1016/j.vaccine.2014.12.002
264-410X/© 2015 The Author. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/3.0/).
to treatment of invasive cancers and palliative care. The introduc-
tion of HPV vaccine should not undermine or divert funding from
developing or maintaining effective screening programmes for cer-
vical cancer. HPV vaccination is a primary prevention tool and does
not eliminate the need for screening later in life, since the vac-
cines do not protect against all high-risk HPV types. Opportunities
to link the introduction of HPV vaccine to other programmes target-
ing young people should be sought (e.g. through adolescent health
services). However, the introduction of HPV vaccination should not
be deferred because other relevant interventions cannot be imple-
mented at the same time.
Experience with various delivery strategies including cam-
paigns, health facility, and outreach/school-based is still accumu-
lating. Countries should use approaches that are (i) compatible with
their delivery infrastructure and cold chain capacity, (ii) affordable,
cost-effective and sustainable and (iii) achieve the highest possible
coverage. If countries consider phased introduction, priority should
be given to strategies that include populations which are likely to
have less access to screening for cervical cancer later in life.
Primary and secondary target groups:  For the prevention of cer-
vical cancer, the WHO-recommended target age group for HPV
vaccination is girls aged 9–13 years, prior to becoming sexually
active. This is because HPV vaccines are most efﬁcacious in those
who have not previously been exposed to the virus.
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Vaccination strategies should initially prioritize high coverage
n the WHO-recommended primary target population of young
emales 9–13 years of age. Vaccination of secondary target popula-
ions of older adolescent females or young women is recommended
nly if this is feasible, affordable, cost effective, and does not divert
esources from vaccinating the primary target population or from
ffective cervical cancer screening programmes.
HPV vaccination of males is not recommended as a priority,
specially in resource-constrained settings, as the available evi-
ence indicates that the ﬁrst priority should be for cervical cancer
eduction by timely vaccination of young females and high cover-
ge with each dose.
Vaccination schedule: Following a review of the evidence demon-
trating that post-vaccination antibody GMCs were shown to
e non-inferior, and recognizing cost-saving and programmatic
dvantages, WHO  has changed its previous recommendation of
 3-dose schedule to a 2-dose schedule, with increased ﬂexibil-
ty in the interval between doses which may  facilitate vaccine
ptake.
For both the bivalent and quadrivalent HPV vaccines, a 2-dose
chedule with a 6-month interval between doses is recommended
or females younger than 15 years. Those who are >15 years at
he time of the second dose are also adequately covered by 2
oses.
There is no maximum recommended interval between doses.
owever, an interval no greater than 12–15 months is suggested in
rder to complete the schedule promptly and before becoming sex-
ally active. If the interval between doses is shorter than 5 months,
 third dose should be given at least 6 months after the ﬁrst dose.
A 3-dose schedule (0, 1–2, 6 months) is recommended for
emales aged 15 years and older, and for those known to be
mmunocompromised and/or HIV-infected (regardless of whether
hey are receiving antiretroviral therapy). It is not necessary to
creen for HPV infection or HIV infection prior to HPV vaccination.
Co-administration with other vaccines: Both HPV vaccines can
e co-administered with other non-live and live vaccines using
eparate syringes and different injection sites.
Interchangeable use of HPV vaccines: Limited data are available on
he safety, immunogenicity or efﬁcacy of the 2 HPV vaccines when
sed interchangeably. The bivalent and quadrivalent vaccines have
ifferent characteristics, components and indications, and in set-
ings where both may  be in use, every effort should be made to
dminister the same vaccine for all doses. However, if the vac-
ine used for prior dose(s) is unknown or unavailable, either of the
PV vaccines can be administered to complete the recommended
chedule.
Safety: Adverse events following HPV vaccination are gener-
lly non-serious and of short duration. The vaccines can be used
n persons who are immunocompromised and/or HIV infected.
ata on the safety of HPV vaccination in pregnancy are limited,
nd HPV vaccination of pregnant women should be avoided. If a
oung female becomes pregnant after initiating the vaccination
eries, the remaining dose(s) should be delayed until after the
regnancy is completed. Breastfeeding is not a contraindication for
PV vaccination. Available evidence does not indicate an increased
isk of adverse events linked to the vaccine in either the moth-
rs or their babies after administration of HPV vaccine to lactating
emales.
[ (2015) 4383–4384
HPV vaccines should not be given to anyone who  has experi-
enced a severe allergic reaction after a previous vaccine dose, or to
a component of the vaccine.
Travellers and health-care workers: Travellers and health-care
workers are not at special risk of contracting HPV infection
and there are no speciﬁc vaccination recommendations for these
groups.
Choice of HPV vaccine: The choice of HPV vaccine should be
based on the assessment of locally relevant data and on a num-
ber of factors, including the scale of the prevailing HPV-associated
public health problem (cervical cancer, other anogenital cancers,
or anogenital warts) and the population for which the vaccine
has been approved. Decision-makers should also consider unique
product characteristics, such as price, supply, and programmatic
considerations.
Monitoring: Monitoring HPV disease is not a prerequisite for
the initiation of a HPV vaccination programme nor is it an essen-
tial requirement of a programme. Monitoring the impact of HPV
vaccine will be complex and should be done with good technical
support and a clear understanding of the caveats to avoid drawing
erroneous conclusions. Complete and accurate information on HPV
vaccine coverage by dose and age is needed for programme perfor-
mance monitoring and also for interpretation of data on measures
of the vaccine’s impact.
Monitoring the prevalence of infection by HPV genotype among
sexually active young women  can provide an early indication of
vaccine effectiveness but requires a considerable commitment of
resources for at least 5–10 years; this strategy is therefore not
recommended for all countries [3]. However, all countries should
consider establishing, or improving, reporting to comprehensive
cancer registries or speciﬁc cervical cancer registries [4]. Cervi-
cal cancer registries are necessary to measure the impact of HPV
vaccine programmes and of cervical cancer screening.
As with the introduction of any new vaccine, post-marketing
surveillance arrangements should be in place to monitor safety. The
prompt and rigorous investigation of any serious adverse events
serves to maintain conﬁdence in the immunization programme.
Research priorities: Further research to generate data on the
longer-term clinical effectiveness and the duration of protection
after 2-dose and 3-dose schedules is needed. Multicentre stud-
ies in low-income countries among healthy young females and
among special populations (e.g. HIV-infected, malnourished ado-
lescents, endemic malaria infection) would provide additional
evidence of the impact of the vaccine in those populations. The
cost-effectiveness and impact of 2-dose versus 3-dose vaccination
schedules in low- and middle-income settings require further eval-
uation.
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